{"id":16799,"date":"2021-01-05T01:25:33","date_gmt":"2021-01-04T22:25:33","guid":{"rendered":"https:\/\/www.klimikdergisi.org\/\/2021\/01\/05\/kronik-hepatit-b-hastalarinin-bes-yillik-tedavi-sonuclarinin-degerlendirilmesi\/"},"modified":"2021-01-05T01:25:33","modified_gmt":"2021-01-04T22:25:33","slug":"kronik-hepatit-b-hastalarinin-bes-yillik-tedavi-sonuclarinin-degerlendirilmesi","status":"publish","type":"post","link":"https:\/\/www.klimikdergisi.org\/tr\/2021\/01\/05\/kronik-hepatit-b-hastalarinin-bes-yillik-tedavi-sonuclarinin-degerlendirilmesi\/","title":{"rendered":"Kronik Hepatit B Hastalar\u0131n\u0131n Be\u015f Y\u0131ll\u0131k Tedavi Sonu\u00e7lar\u0131n\u0131n De\u011ferlendirilmesi"},"content":{"rendered":"<h1>\u00d6zet<\/h1>\n<p> <strong>Ama\u00e7<\/strong>: \u0130nterferon-alfa, kronik hepatit B tedavisinde iki dekadd\u0131r kullan\u0131lmaktad\u0131r. Son y\u0131llarda tedavide oral antivirallerin kullan\u0131lmaya ba\u015flanmas\u0131yla \u00f6nemli geli\u015fmeler olmu\u015ftur. Bu \u00e7al\u0131\u015fmada kronik hepatit B tedavisindeki son 5 y\u0131ll\u0131k tedavi sonu\u00e7lar\u0131m\u0131z\u0131n de\u011ferlendirilmesi ama\u00e7lanm\u0131\u015ft\u0131r.\u00a0<\/p>\n<p> <strong>Y\u00f6ntemler<\/strong>: 2004-2009 y\u0131llar\u0131 aras\u0131nda Kocaeli \u00dcniversitesi T\u0131p Fak\u00fcltesi \u0130nfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji Poliklini\u011finde kronik hepatit B tedavisi alan toplam 583 hastadan 167\u2019si \u00e7al\u0131\u015fmaya dahil edildi. Di\u011fer hastalar tedavi s\u00fcreleri bir y\u0131ldan k\u0131sa oldu\u011fu i\u00e7in \u00e7al\u0131\u015fmaya al\u0131nmad\u0131.\u00a0<\/p>\n<p> <strong>Bulgular<\/strong>: Hastalar\u0131n 27 (%16)\u2019si HBeAg-pozitif, 140 (%84)\u2019\u0131 ise HBeAg-negatifti. Hastalar\u0131n tamam\u0131 genotip D olarak saptand\u0131. \u00c7al\u0131\u015fma grubu, 40 (%24)\u2019\u0131 sadece interferon alm\u0131\u015f ve takipleri en az bir y\u0131ld\u0131r devam eden hen\u00fcz relaps olmam\u0131\u015f hastalar; 70 (%42)\u2019i interferon tedavisini bitirdikten sonra relaps olan ve oral antiviraller ile tedaviye devam eden hastalar ve 57 (%34)\u2019si ya kontrindikasyonu olan ya da di\u011fer sebeplerden interferon kullanamay\u0131p sadece oral antiviral kullanan hastalardan olu\u015fmaktayd\u0131. \u0130nterferon sonras\u0131 ya da interferon kullanmaks\u0131z\u0131n, lamivudin ba\u015flanan 55 hastadan 18 (%32)\u2019inde; adefovir ba\u015flanan 53 hastadan 4 (%8)\u2019\u00fcnde kulland\u0131klar\u0131 ilaca diren\u00e7 saptand\u0131. Lamivudin direnci geli\u015fenlerden sadece 2\u2019si \u00f6ncesinde interferon kullanm\u0131\u015ft\u0131. Hastalar\u0131n takiplerinde 27 (%16) HBeAg-pozitif hastan\u0131n d\u00f6rd\u00fcnde anti-HBe, 167 hastan\u0131n da 2 (%1)\u2019sinde anti-HBs geli\u015fti.<\/p>\n<p> <strong>Sonu\u00e7lar<\/strong>: Kronik hepatit B ya\u015fam boyu s\u00fcren takip ve tedavi gerektirir. O y\u00fczden tedavi de\u011fi\u015fiklikleri de her hastaya \u00f6zel olmal\u0131d\u0131r. Tedaviye, e\u011fer uygunsa, s\u00fcresi belli bir tedavi olan interferonla ba\u015flanmas\u0131, gerekirse de oral antiviralle devam edilmesi, oral antivirallere diren\u00e7 geli\u015fimini geciktirebilir.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00d6zet Ama\u00e7: \u0130nterferon-alfa, kronik hepatit B tedavisinde iki dekadd\u0131r kullan\u0131lmaktad\u0131r. Son y\u0131llarda tedavide oral antivirallerin kullan\u0131lmaya ba\u015flanmas\u0131yla \u00f6nemli geli\u015fmeler olmu\u015ftur. Bu \u00e7al\u0131\u015fmada kronik hepatit B tedavisindeki son 5 y\u0131ll\u0131k tedavi sonu\u00e7lar\u0131m\u0131z\u0131n de\u011ferlendirilmesi ama\u00e7lanm\u0131\u015ft\u0131r.\u00a0 Y\u00f6ntemler: 2004-2009 y\u0131llar\u0131 aras\u0131nda Kocaeli \u00dcniversitesi T\u0131p Fak\u00fcltesi \u0130nfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji Poliklini\u011finde kronik hepatit B tedavisi alan toplam 583 hastadan [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5129],"tags":[3328,3922,3866],"class_list":["post-16799","post","type-post","status-publish","format-standard","hentry","category-ozgun-arastirma","tag-kronik-hepatit-b","tag-oral-antiviral","tag-pegile-interferon"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts\/16799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/comments?post=16799"}],"version-history":[{"count":0,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts\/16799\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/media?parent=16799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/categories?post=16799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/tags?post=16799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}